Crenessity is expected to be available commercially in approximately 1 week through PANTHERx Rare, a specialty pharmacy. The Food and Drug Administration (FDA) has approved Crenessity TM (crinecerfont ...

The US Food and Drug Administration has approved crinecerfont (Crenessity) for use in combination with glucocorticoids in the treatment of adults and children aged 4 years or older with classic ...

Please provide your email address to receive an email when new articles are posted on . Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal ...

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH) due to ...

People with classic congenital adrenal hyperplasia (CAH) may suffer from impaired bone health, largely due to standard treatments. Most often caused by a genetic mutation in the 21-hydroxylase enzyme, ...

People with classic congenital adrenal hyperplasia (CAH) often experience fertility issues, but hormone-balancing treatment can help. This rare genetic disorder is most often caused by a ...

Credit: Shutterstock. Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist. A phase 3 study evaluating the efficacy and safety of ...

A 29-year-old man was seen 2 years ago to transfer his care from pediatric to adult endocrinology. He was diagnosed at birth with classic congenital adrenal hyperplasia from 21-hydroxylase deficiency ...

Citation: Stewart S (2013) Rare diseases 5: treating congenital adrenal hyperplasia. Nursing Times; 109: 49/50, 23. Author: Sue Stewart is clinical nurse specialist in endocrinology and genetics at ...